| Literature DB >> 23447498 |
Jarrah R Spencer1, Keturah M E Darbyshire, Aurelie A Boucher, Mohammed A Kashem, Leonora E Long, Iain S McGregor, Tim Karl, Jonathon C Arnold.
Abstract
Neuregulin 1 (NRG1) is linked to an increased risk of developing schizophrenia and cannabis dependence. Mice that are hypomorphic for Nrg1 (Nrg1 HET mice) display schizophrenia-relevant behavioral phenotypes and aberrant expression of serotonin and glutamate receptors. Nrg1 HET mice also display idiosyncratic responses to the main psychoactive constituent of cannabis, Δ(9)-tetrahydrocannabinol (THC). To gain traction on the molecular pathways disrupted by Nrg1 hypomorphism and Nrg1-cannabinoid interactions we conducted a proteomic study. Adolescent wildtype (WT) and Nrg1 HET mice were exposed to repeated injections of vehicle or THC and their hippocampi were submitted to 2D gel proteomics. Comparison of WT and Nrg1 HET mice identified proteins linked to molecular changes in schizophrenia that have not been previously associated with Nrg1. These proteins are involved in vesicular release of neurotransmitters such as SNARE proteins; enzymes impacting serotonergic neurotransmission, and proteins affecting growth factor expression. Nrg1 HET mice treated with THC expressed a distinct protein expression signature compared to WT mice. Replicating prior findings, THC caused proteomic changes in WT mice suggestive of greater oxidative stress and neurodegeneration. We have previously observed that THC selectively increased hippocampal NMDA receptor binding of adolescent Nrg1 HET mice. Here we observed outcomes consistent with heightened NMDA-mediated glutamatergic neurotransmission. This included differential expression of proteins involved in NMDA receptor trafficking to the synaptic membrane; lipid raft stabilization of synaptic NMDA receptors; and homeostatic responses to dampen excitotoxicity. These findings uncover novel proteins altered in response to Nrg1 hypomorphism and Nrg1-cannabinoid interactions that improves our molecular understanding of Nrg1 signaling and Nrg1-mediated genetic vulnerability to the neurobehavioral effects of cannabinoids.Entities:
Keywords: Nrg1; THC; hippocampus; mouse; proteomics; schizophrenia
Year: 2013 PMID: 23447498 PMCID: PMC3581856 DOI: 10.3389/fncel.2013.00015
Source DB: PubMed Journal: Front Cell Neurosci ISSN: 1662-5102 Impact factor: 5.505
Adolescent hippocampal proteomics comparing adolescent vehicle-treated WT and .
| 11755 | Syntaxin-1A | STX1A | O35526 | 5.14 | 33,054 | 63 | 5 | 20 | 2.996 | 0.00123 |
| 11358 | Beta-soluble NSF attachment protein | β-SNAP | P28663 | 5.32 | 33,557 | 80 | 5 | 33 | −8.897 | 0.02521 |
| 11673 | Syntaxin-7 | STX7 | O70439 | 5.6 | 29,821 | 55 | 4 | 22 | 2.118 | 0.00333 |
| 11737 | Dynactin subunit 2 | DCTN2 | Q99KJ8 | 5.14 | 44,117 | 94 | 8 | 21 | 2.96 | 0.03845 |
| 11800 | ADP-ribosyl cyclase 2 | BST-1 | Q64277 | 5.49 | 34,616 | 85 | 5 | 37 | −1.516 | 0.04099 |
| 11967 | Tryptophan 5-hydroxylase 1 | TPH1 | P17532 | 6.06 | 51,343 | 82 | 7 | 17 | −3.353 | 0.04087 |
| 11670 | Serotonin N-acetyltransferase | AA-NAT | O88816 | 7.01 | 23,069 | 56 | 3 | 26 | 1.549 | 0.00076 |
| 11646 | Secreted protein acidic and rich in cysteine | SPARC | P07214 | 4.77 | 34,450 | 71 | 5 | 16 | 1.388 | 0.04557 |
| 11294 | Glypican 6 | GPC6 | Q9R087 | 5.32 | 63,057 | 86 | 7 | 20 | 2.515 | 0.01623 |
| 11419 | Fibroblast growth factor 14 | FGF14 | P70379 | 10.11 | 27,764 | 74 | 5 | 29 | −1.61 | 0.02358 |
| 11005 | TNFAIP3-interacting protein 2 | ABIN2 | Q99JG7 | 6.03 | 49,094 | 78 | 8 | 23 | −1.792 | 0.00449 |
| 11105 | Cell death regulator Aven | AVEN | Q9D9K3 | 4.92 | 37,195 | 59 | 5 | 21 | −1.887 | 0.03471 |
| 12856 | Regulator of G-protein signaling 10 | RGS10 | Q9CQE5 | 6.36 | 21,151 | 66 | 4 | 44 | 1.805 | 8.22E-05 |
| 12115 | Phosphoserine phosphatase | PSPH | Q99LS3 | 5.81 | 25,096 | 56 | 4 | 36 | 1.434 | 0.01847 |
| 11051 | Calcium/calmodulin-dependent 3′,5′-cyclic nucleotide phosphodiesterase 1A | PDE1A | Q61481 | 5.67 | 64,529 | 82 | 7 | 15 | −1.514 | 0.00902 |
| 11988 | Galanin-like peptide | GALP | Q810H5 | 6.41 | 12,773 | 61 | 3 | 35 | −5.496 | 0.03014 |
| 12051 | Glyoxalase domain-containing protein 5 | GLOD5 | Q9D8I3 | 5.12 | 16,595 | 59 | 4 | 40 | −1.827 | 0.03871 |
Figure 1Adolescent hippocampal proteomics comparing adolescent vehicle-treated WT and Representative 2DE gel images showing positions of significantly altered protein spots [the horizontal axis split by isoelectric point, vertical axis split by molecular weight; STX1A (spot 11755); TPH1 (spot 11967); β-SNAP (spot 11358); SPARC (spot 11646); GPC6 (spot 11294)]; and (B) Exemplar normalized volumes of altered proteins i.e., STX1A, β-SNAP and GPC6. The inset for STX1A shows immunoblots against STX1A and loading control alpha-tubulin (TUBA), confirming greater expression of STX1A in Nrg1 HET versus WT mice.
Adolescent hippocampal proteomics comparing adolescent WT mice treated with vehicle and THC.
| 11418 | Glutathione S-transferase Mu 2 | GSTM2 | P15626 | 6.9 | 25,717 | 73 | 5 | 20 | −1.759 | 0.02679 |
| 11769 | Heat shock 70 kDa protein 4 | HSPA4 | Q61316 | 5.15 | 94,133 | 95 | 8 | 14 | 2.137 | 0.04305 |
| 11103 | Calretinin | CALB2 | Q08331 | 4.94 | 31,373 | 66 | 4 | 21 | −1.748 | 0.03045 |
| 11677 | ADP-ribosylation factor-like protein 1 | ARL1 | P61211 | 5.63 | 20,412 | 57 | 3 | 20 | −2.869 | 0.04051 |
Figure 2Adolescent hippocampal proteomics comparing adolescent WT mice treated with vehicle and THC. (A) Representative 2DE gel images showing positions of significantly altered protein spots, the horizontal axis split by isoelectric point, vertical axis split by molecular weight; [CALB2 (spot 11103); ARL1 (spot 11677); GSTM2 (spot 11418); HSPA4 (spot 11769)]; and (B) Exemplar normalized volumes of altered proteins i.e., CALB2, ARL1, and GSTM2.
Figure 3Adolescent hippocampal proteomics comparing adolescent Representative 2D E gel images showing positions of significantly altered protein spots (the horizontal axis split by isoelectric point, vertical axis split by molecular weight; [GPSM2 (spot 11713); APOA1 (spot 11674); NAPEPLD (spot 11060); OTOR (spot 12395)]; and (B) exemplar normalized volumes of altered proteins i.e., GPSM2, APOA1 and NAPEPLD.
Figure 4Schematic representation of altered proteins. (A) Proteins with different expression in Nrg1 HET mice relative to WT controls; and (B) Proteins with different expression in THC administered Nrg1 HET mice relative to vehicle treated controls.
Adolescent hippocampal proteomics comparing adolescent .
| 11396 | Flotillin-1 | FLOT1 | O08917 | 6.71 | 47,513 | 82 | 6 | 16 | 1.54 | 0.001985 |
| 11674 | Apolipoprotein A-I | APOA1 | Q00623 | 5.64 | 30,616 | 73 | 5 | 19 | 2.069 | 0.003538 |
| 11713 | G-protein-signaling modulator 2 | GPSM2 | Q8VDU0 | 6.49 | 75,591 | 77 | 7 | 15 | −2.648 | 0.04831 |
| 12338 | Programmed cell death protein 2 (fragment) | PDCD2 | Q6RI66 | 5.24 | 19,190 | 66 | 9 | 19 | 1.169 | 0.0391 |
| 11060 | N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D | NAPEPLD | Q8BH82 | 5.63 | 45,816 | 78 | 6 | 21 | 2.334 | 0.02612 |
| 11078 | Interleukin-2 | IL-2 | P04351 | 4.66 | 19,400 | 58 | 3 | 34 | −1.48 | 0.03401 |
| 11273 | Translocon-associated protein subunit alpha | SSR1 | Q9CY50 | 4.36 | 32,065 | 56 | 4 | 20 | −3.383 | 0.02365 |
| 11684 | Carbonic anhydrase 3 | CA3 | P16015 | 6.89 | 29,366 | 97 | 42 | −1.293 | 0.03876 | |
| 11348 | Vacuolar protein-sorting-associated protein 25 | VPS25 | Q9CQ80 | 5.97 | 20,748 | 62 | 4 | 33 | −3.211 | 0.04376 |
| 12395 | Otoraplin | OTOR | Q9JIE3 | 4.77 | 14,328 | 61 | 3 | 21 | 3.159 | 0.0296 |